Excerpted from the Janssen Inc. press release:
We are excited to share that men with metastatic castration-resistant prostate cancer (mCRPC) in Ontario now have access to a therapy that can be used prior to chemotherapy. Effective February 13, 2014, ZYTIGA® (abiraterone acetate) is being reimbursed by the public drug plan for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT), who meet specific criteria. This is important news for men who want a treatment option that can be used earlier in advanced disease, helps delay disease progression, shows a consistent trend in improving overall survival and improves overall quality of life.
Men and their caregivers are encouraged to speak to their healthcare providers to learn more about the specific eligibility criteria that are required to be met for reimbursement of ZYTIGA® in Ontario.
We at Prostate Cancer Canada Network Brampton took part in a campaign to have Zytiga® approved for reimbursement for men with mCRPC in 2012, in support of Percy Bedard of Zurich, ON. Approval was granted by the ministry that Fall and Percy went on Zytiga, which helped him briefly.
It is our hope that being able to take Zytiga® after failure of ADT but before undergoing chemotherapy first might serve to spare some men from the unpleasant side effects that so often accompany chemotherapy. We do recognize that, like all available medications, Zytiga® may not work for everybody. To those for whom it does work, it could possibly lead to a longer, better life.